dermatomyositis: Dermatomyositis (DM) is a type of idiopathic inflammatory myopathy characterized by evocative skin lesions and symmetrical proximal muscle weakness.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
216 |
4. Check minimum number of eventsNone |
216 |
5. Include endpointsNone |
216 |
6. Filter based on genotype QC (FinnGen only) |
189 |
Control definitions (FinnGen only)
- Control exclude
- M13_SYSTCONNECT
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M33
- Name in latin
- Dermato[poly]myositis non specificata
Similar endpoints
↥List of similar endpoints to
Dermatopolymyositis, unspecified
based on the number of shared cases.
Similar with more cases:
- Dermatopolymyositis (FG)
- Dermatopolymyositis
- Systemic connective tissue disorders
- Autoimmune diseases related-to ILD
- Autoimmune diseases
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 919 | 568 | 346 |
| Only index persons | 811 | 503 | 308 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.02 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 59.15 | 58.28 | 60.73 |
| Only index persons | 57.73 | 56.78 | 59.29 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 189 | 112 | 77 |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | 0.04 |
| Median age at first event (years) | 57.56 | 54.55 | 61.95 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 196
- Matched controls
- 1960
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M33.9
ICD-10 Finland
Dermatopolymyositis, unspecified
+∞
274.6
193
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
19.6
100.5
106
111
M33.1
ICD-10 Finland
Other dermatomyositis
+∞
84.7
75
*
L04AX03
ATC
methotrexate; systemic
16.5
83.8
92
100
L04AX01
ATC
azathioprine; systemic
33.1
82.8
57
24
P01BA02
ATC
hydroxychloroquine; oral
16.3
74.4
77
75
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
16.5
56.2
53
43
M33.2
ICD-10 Finland
Polymyositis
+∞
46.8
43
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
8.4
44.5
145
497
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
10.2
41.8
55
72
M05BA04
ATC
alendronic acid; oral
10.1
41.3
55
73
H02AB06
ATC
prednisolone; systemic
9.4
38.7
164
691
M60.9
ICD-10 Finland
Myositis, unspecified
219.0
36.1
36
*
L04AA06
ATC
mycophenolic acid; systemic
51.8
32.3
38
9
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
9.7
31.5
41
52
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
354.0
30.7
30
*
NJ3BG
NOMESCO Finland
MRI examination of extremities with high intensity magnet
87.8
27.6
30
*
J99.1*M33.9
ICD-10 Finland
Respiratory disorders in dermatopolymyositis
+∞
26.7
25
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
6.4
25.1
49
97
NXL00
NOMESCO Finland
Biopsy of muscle
142.4
24.2
25
*
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
7.2
23.5
39
65
NJ3CG
NOMESCO Finland
Extensive MRI examination of extremities with median high magnet
74.4
23.5
26
*
G72.9
ICD-10 Finland
Myopathy, unspecified
37.5
23.2
29
9
M60.8
ICD-10 Finland
Other myositis
233.8
21.0
21
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
4.1
20.9
95
368
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.5
15.4
132
729
L04AD01
ATC
ciclosporin; systemic
23.3
15.0
21
10
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
+∞
14.8
14
*
ZX120
NOMESCO Finland
Intravenous
4.4
14.1
40
107
H02AB07
ATC
prednisone; oral
4.0
13.9
47
143
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.8
13.1
47
149
J99.1*M33.2
ICD-10 Finland
Respiratory disorders in polymyositis
+∞
12.6
12
*
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
40.3
12.4
15
*
L01BA01
ATC
methotrexate; systemic
11.1
11.9
22
22
M33
ICD-10 Finland
Dermatopolymyositis
+∞
11.6
11
*
M35.1
ICD-10 Finland
Other overlap syndromes
+∞
11.6
11
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.0
11.3
71
315
L04AA01
ATC
[U] ciclosporin
30.0
10.9
14
5
M33.0
ICD-10 Finland
Juvenile dermatomyositis
+∞
10.5
10
*
XG410
NOMESCO Finland
Flow-volume spirometry
8.4
10.2
22
29
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
27.7
9.9
13
5
D07AB08
ATC
desonide; topical
3.5
9.8
39
131
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
10.9
9.7
18
18
ZY020
NOMESCO Finland
Telephone, letter or other consultation without direct patient contact
4.3
9.3
26
68
HA1AA
NOMESCO Finland
X-ray mammography
3.8
9.2
31
93
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
8.6
9.1
19
24
Z09.0
ICD-10 Finland
Follow-up examination after surgery for other conditions
4.2
8.8
25
66
D07AC01
ATC
betamethasone; topical
2.5
8.7
90
501
JN4BD
NOMESCO Finland
Extensive body CT
3.4
8.7
35
118
1XC02, ,
NOMESCO Finland
93.9
8.5
9
*
M05BA07
ATC
risedronic acid; oral
8.1
8.4
18
24
XA402
NOMESCO Finland
ENMG
8.8
8.3
17
21
R50.9
ICD-10 Finland
Fever, unspecified
3.0
8.2
43
170
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
4.1
8.2
24
65
R13
ICD-10 Finland
Dysphagia
3.8
8.1
26
75
A02BC02
ATC
pantoprazole; systemic
2.7
7.8
153
1117
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
10.7
7.7
14
14
SPAT1229
SPAT
Assessment of need for aid
4.1
7.6
22
59
E000001, ,
ATC
2.6
7.5
51
231
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.2
7.4
32
113
J99.1
ICD-10 Finland
Respiratory disorders in other diffuse connective tissue disorders
+∞
7.3
7
*
XPX04
NOMESCO Finland
Angioscopy
+∞
7.3
7
*
NJ3DG
NOMESCO Finland
Very extensive MRI examination of extremities with high intensity magnet
+∞
7.3
7
*
L28
ICPC
Limited function/disability (L)
2.6
7.3
52
240
L88
ICPC
Rheumatoid/seropositive arthritis
6.1
7.3
19
34
L99
ICPC
Musculoskeletal disease other
8.4
7.3
15
19
TPH04
NOMESCO Finland
Cathetrisation of vein
2.5
7.2
58
284
NGA20
NOMESCO Finland
Exploration of soft tissue knee or lower leg, open
31.3
7.2
9
*
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
12.7
7.2
12
10
M35.3
ICD-10 Finland
Polymyalgia rheumatica
8.8
7.0
14
17
E0000UV, ,
ATC
2.2
6.9
98
611
R2110
NOMESCO Finland
Giving the first information
4.1
6.7
19
50
M05BX04
ATC
denosumab; parenteral
3.8
6.6
21
60
R06.0
ICD-10 Finland
Dyspnoea
2.3
6.4
66
359
UJF30
NOMESCO Finland
Ileoscopy through colon
3.0
6.4
31
117
N03AX16
ATC
[U] pregabalin
2.3
6.3
57
293
L30.9
ICD-10 Finland
Dermatitis, unspecified
2.4
6.2
54
272
TGC00
NOMESCO Finland
Bronchial lavation
7.1
6.2
14
21
D07AC13
ATC
mometasone; topical
2.2
6.1
67
372
C03CA01
ATC
furosemide; systemic
2.2
6.1
68
380
C08CA05
ATC
nifedipine; systemic
3.8
6.0
19
54
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
90
39
41.82
132.53
1.9
1.2
72.40
—
u/ml
—
5
0
72
7
160.89
71.70
4.0
1.1
6.32
5.10
u/l
—
67
7
70
9
119.68
67.46
1.4
1.0
—
—
—
0
0
69
67
15.35
66.32
2.8
1.4
6.01
3.57
iu/ml
0.50
21
15
163
538
13.06
55.48
14.8
1.9
231.44
184.25
u/l
0.54
163
508
50
49
13.36
46.89
1.9
1.1
0.21
0.25
g/l
1.43
50
49
50
51
12.82
45.62
1.9
1.1
1.13
1.25
g/l
1.76
50
51
39
5
96.61
36.35
1.4
1.0
—
—
—
0
0
39
45
10.57
32.18
1.6
1.4
330.28
0.08
iu/ml
—
10
9
165
1014
4.97
17.20
22.2
10.1
4.20
4.07
e9/l
0.34
160
881
51
170
3.70
13.23
2.3
2.0
398.98
376.79
nmol/l
0.11
51
159
21
15
15.51
13.10
1.6
1.1
—
—
—
0
0
149
949
3.38
12.53
6.3
3.7
0.00
7.88
estimate
0.50
41
206
148
942
3.33
12.39
6.3
3.7
0.00
0.00
estimate
-0.00
40
203
149
963
3.28
11.93
6.5
3.7
0.00
1.55
estimate
0.50
40
193
18
12
16.37
11.56
1.7
1.1
—
—
—
0
0
18
13
15.10
11.21
1.7
1.1
—
—
—
0
0
18
13
15.10
11.21
1.7
1.1
—
—
—
0
0
69
303
2.97
11.21
3.1
2.2
12.38
13.50
umol/l
0.56
69
283
141
902
3.01
11.13
12.0
7.1
1.22
1.21
mmol/l
0.56
125
778
27
64
4.73
10.95
3.8
2.9
—
—
—
0
0
18
14
14.02
10.89
1.7
1.1
—
—
—
0
0
17
13
14.18
10.37
1.5
1.2
—
—
—
0
0
13
5
27.66
9.95
1.6
1.6
—
—
—
0
0
62
277
2.81
9.57
2.5
1.9
—
—
—
0
0
85
450
2.57
9.30
3.3
2.0
3.15
2.79
mg/l
0.85
77
393
51
211
2.92
9.02
2.0
1.7
—
—
—
0
0
19
40
5.15
8.79
1.4
1.6
—
—
—
0
0
20
45
4.84
8.58
10.6
5.4
3.81
4.86
ratio
0.12
14
20
94
551
2.36
7.93
5.8
3.2
1092.06
1171.62
ng/l
0.10
87
461
20
49
4.43
7.74
7.4
2.9
0.00
0.00
g/l
-0.00
20
49
46
199
2.71
7.38
2.1
1.7
—
—
—
0
0
90
534
2.27
7.21
7.2
3.9
0.00
0.01
estimate
0.50
39
189
18
44
4.40
6.98
1.6
1.2
—
—
—
0
0
63
329
2.35
6.74
1.5
1.3
60.45
35.11
iu/ml
0.49
17
102
27
91
3.28
6.69
3.5
3.5
1.38
1.90
mmol/l
0.19
22
74
18
48
4.03
6.24
1.7
1.5
—
—
—
0
0
18
50
3.86
5.91
1.6
1.5
—
—
—
0
0
105
705
2.05
5.74
6.3
3.6
0.00
0.02
estimate
0.68
37
172
26
94
3.04
5.73
1.8
1.8
—
—
—
0
0
16
42
4.06
5.66
1.8
1.5
—
—
—
0
0
11
14
8.25
5.42
1.9
1.4
2.48
4.08
mg/l
0.81
11
14
82
516
2.01
5.25
5.1
3.1
0.00
0.15
estimate
0.50
36
163
9
9
10.41
5.08
1.8
5.7
335.00
779.33
mg
—
9
9
71
431
2.02
4.98
1.4
1.2
0.83
1.92
u/ml
1.11
17
120
115
827
1.95
4.88
4.4
2.9
238.28
116.92
ug/l
1.92
110
774
17
52
3.48
4.87
1.2
1.2
—
—
—
0
0
33
149
2.46
4.77
12.2
7.0
10.48
9.66
mmol/l
0.26
33
144
89
597
1.90
4.58
5.8
2.9
55.54
32.53
u/l
2.00
84
573
12
23
5.48
4.53
1.2
1.1
—
—
—
0
0
10
15
6.96
4.53
1.7
1.5
—
—
—
0
0
54
306
2.06
4.52
1.3
1.3
35.16
9.89
u/ml
0.61
16
115
20
72
2.98
4.44
1.5
1.5
1.28
1.56
g/l
0.82
20
65
84
559
1.88
4.39
3.3
2.4
56.51
71.41
u/l
0.70
79
520
31
142
2.41
4.33
2.1
2.5
0.24
0.28
e6/l
0.13
31
133
13
29
4.72
4.33
1.2
1.2
3.50
8.30
u/ml
—
6
10
52
298
2.01
4.20
2.0
1.6
1214.21
1183.43
nmol/l
0.09
45
229
10
18
5.79
4.03
1.7
1.4
—
—
—
0
0
13
32
4.28
3.98
1.5
1.6
—
—
—
0
0
13
33
4.14
3.87
1.2
1.4
—
—
—
0
0
70
456
1.83
3.81
4.6
2.9
345.89
339.03
umol/l
0.24
64
396
7
8
9.02
3.80
2.7
2.8
31.74
44.51
g/l
—
7
8
6
5
12.32
3.78
2.2
6.2
904.33
1252.00
u/ml
—
6
5
12
29
4.34
3.77
1.2
1.3
133.76
156.49
au/ml
—
5
11
12
29
4.34
3.77
1.6
1.4
—
—
—
0
0
10
21
4.96
3.61
2.0
1.3
—
—
—
0
0
16
58
2.91
3.51
3.4
1.9
25.29
25.14
mmol/l
0.03
16
58
77
530
1.75
3.42
4.2
3.1
0.23
0.40
e6/l
0.89
63
384
8
14
5.91
3.37
1.1
1.0
—
—
—
0
0
13
40
3.41
3.21
2.0
1.4
—
—
—
0
0
12
35
3.58
3.17
1.6
1.5
—
—
—
0
0
51
318
1.82
3.13
3.9
2.9
0.58
0.88
e6/l
0.80
33
161
8
16
5.16
3.08
1.0
1.1
—
—
—
0
0
8
16
5.16
3.08
1.1
1.2
—
—
—
0
0
11
32
3.58
2.95
1.2
1.2
—
—
—
0
0
77
548
1.67
2.94
2.1
1.6
17.83
21.24
nmol/l
1.63
70
456
35
203
1.88
2.68
8.1
8.3
1.78
1.08
mmol/l
0.31
29
173
24
122
2.10
2.64
1.5
1.5
—
—
—
0
0
6
12
5.12
2.42
1.0
1.3
—
—
—
0
0
6
12
5.12
2.42
1.7
1.4
—
—
—
0
0
5
8
6.38
2.38
1.4
1.1
—
—
—
0
0
5
8
6.38
2.38
1.4
1.1
—
—
—
0
0
7
17
4.23
2.38
1.1
1.3
—
—
—
0
0
58
404
1.62
2.33
6.8
3.7
1.02
1.02
kg/l
0.01
48
266
6
13
4.72
2.29
1.2
1.2
—
—
—
0
0
10
35
2.95
2.24
2.4
1.3
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
12
48
2.60
2.23
2.7
2.2
0.34
0.34
iu/ml
—
6
25
5
9
5.67
2.22
1.0
1.0
—
—
—
0
0
10
38
2.72
2.03
1.0
1.1
—
20.26
—
0
5
13
57
2.37
2.02
1.2
1.5
—
—
—
0
0
7
21
3.42
1.98
1.3
1.8
—
—
—
0
0
88
694
1.49
1.98
7.2
3.7
96.39
33.76
ng/l
1.09
83
492
7
22
3.26
1.90
1.6
1.3
—
—
—
0
0
7
22
3.26
1.90
1.3
1.8
—
—
—
0
0
31
193
1.72
1.89
2.7
4.8
2.95
30.44
ug/l
0.69
24
162
13
60
2.25
1.82
1.2
1.4
—
—
—
0
0
10
40
2.58
1.69
1.6
1.4
—
—
—
0
0
42
293
1.55
1.65
4.3
3.0
5.44
1.92
e6/l
1.10
24
138
11
51
2.23
1.53
1.2
1.2
—
—
—
0
0
6
21
2.91
1.51
1.0
1.6
—
—
—
0
0
6
21
2.91
1.51
1.0
1.6
—
—
—
0
0
6
21
2.91
1.51
1.0
1.6
—
—
—
0
0
155
1669
0.66
1.49
6.0
5.1
5.79
5.96
mmol/l
1.25
148
1532
151
1361
1.48
1.48
5.8
4.4
15.18
14.76
pmol/l
1.22
146
1239
5
16
3.18
1.44
1.4
1.9
—
—
—
0
0
5
16
3.18
1.44
1.4
1.9
—
—
—
0
0
5
16
3.18
1.44
1.4
1.9
—
—
—
0
0
39
276
1.52
1.44
1.3
1.5
—
—
—
0
0
74
594
1.39
1.41
4.4
3.9
7.45
8.97
mg/mmol
0.15
51
372
14
75
1.93
1.38
1.6
1.3
—
—
—
0
0
12
62
2.00
1.31
3.2
2.0
—
—
—
0
0
18
109
1.72
1.24
3.7
3.8
24.31
24.54
mmol/l
0.16
18
109
5
19
2.67
1.22
1.0
1.2
—
3.31
—
0
8
5
19
2.67
1.22
4.4
3.8
18.76
98.56
u/ml
—
5
19
180
1703
1.70
1.22
39.3
15.2
18.37
23.44
mg/l
1.85
164
1385
6
26
2.35
1.19
1.3
1.3
—
—
—
0
0
6
26
2.35
1.19
1.3
1.3
—
—
—
0
0
30
213
1.48
1.10
5.7
2.9
5.77
5.89
umol/l
0.04
30
195
5
21
2.42
1.09
1.0
1.6
—
—
—
0
0
153
1632
0.72
1.09
5.1
4.4
1.54
1.27
mmol/l
2.47
146
1496
26
180
1.51
1.07
3.6
3.7
—
—
—
0
0
7
33
2.16
1.06
1.1
1.1
—
—
—
0
0
5
22
2.30
1.04
1.0
1.6
—
—
—
0
0
5
22
2.30
1.04
1.4
1.3
—
—
—
0
0
5
22
2.30
1.04
1.0
1.6
—
—
—
0
0
44
344
1.36
0.96
6.4
3.9
282.47
356.89
ng/l
0.17
34
270
46
364
1.34
0.93
2.2
2.9
2.47
2.45
mmol/l
0.59
41
328
10
56
1.83
0.89
3.1
1.8
—
—
—
0
0
92
807
1.26
0.86
2.8
2.0
98.17
96.55
pmol/l
0.11
57
417
10
57
1.79
0.85
2.2
1.6
—
—
—
0
0
50
409
1.30
0.81
2.0
1.7
1.32
1.36
mg/l
0.05
36
325
8
48
1.69
0.79
1.1
1.2
—
—
—
0
0
5
25
2.03
0.73
1.2
1.2
—
—
—
0
0
7
42
1.69
0.69
3.1
1.5
—
—
—
0
0
23
174
1.36
0.63
4.2
3.6
1.77
2.01
mmol/l
0.15
23
147
16
113
1.45
0.63
1.3
1.2
94.93
122.30
u/ml
—
6
48
8
49
1.66
0.63
1.1
1.2
—
—
—
0
0
53
451
1.24
0.63
2.7
2.4
—
—
—
0
0
8
52
1.56
0.60
1.0
1.3
—
314.05
—
0
28
173
1665
1.33
0.60
31.5
15.6
83.25
80.92
ml/min/173m2
0.60
166
1545
93
846
1.19
0.55
4.0
2.7
—
—
estimate
—
0
0
7
47
1.51
0.48
1.1
1.1
377.57
458.98
mg/l
—
7
47
83
757
1.17
0.46
2.0
2.0
1.59
1.34
mmol/l
1.34
72
632
16
121
1.35
0.46
18.2
8.1
25.69
24.90
mmol/l
0.50
16
121
5
32
1.58
0.42
1.0
1.2
39.44
20.81
u/l
—
5
27
15
114
1.34
0.42
1.3
1.2
209.31
516.99
u/ml
0.52
15
109
167
1616
1.23
0.42
7.1
5.4
1.98
1.89
mu/l
0.44
160
1483
0
15
0.00
0.41
0.0
1.5
—
10.25
—
0
15
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
0
15
0.00
0.41
0.0
1.2
—
—
—
0
0
0
15
0.00
0.41
0.0
1.2
—
—
—
0
0
149
1429
1.18
0.41
41.1
19.5
14.24
13.64
%
5.13
149
1419
0
18
0.00
0.40
0.0
1.1
—
37.55
—
0
11
0
18
0.00
0.40
0.0
1.1
—
519.42
—
0
12
5
36
1.40
0.38
4.2
2.5
15.80
16.52
%
—
5
36
28
238
1.21
0.35
6.4
5.0
32.22
31.62
%
0.14
23
151
40
450
0.86
0.33
3.6
4.8
21.49
21.99
%
0.08
20
233
170
1738
0.84
0.31
6.2
6.0
2.81
2.72
mmol/l
0.71
162
1609
13
102
1.29
0.31
4.0
2.5
0.63
0.60
%
0.15
13
102
11
84
1.33
0.30
1.4
1.3
—
—
—
0
0
7
55
1.28
0.30
1.7
1.6
—
—
—
0
0
13
104
1.27
0.27
4.0
2.5
1.49
1.22
%
0.70
13
104
25
216
1.18
0.27
1.6
1.9
1.75
1.44
%
2.24
17
185
167
1703
0.87
0.24
5.7
5.2
1.43
1.49
mmol/l
0.89
159
1570
0
12
0.00
0.21
0.0
3.5
—
4.73
—
0
12
0
12
0.00
0.21
0.0
3.5
—
10.65
—
0
12
168
1708
0.89
0.19
5.8
5.3
4.75
4.66
mmol/l
0.58
161
1580
32
346
0.91
0.15
2.8
3.3
1.23
0.78
ug/l
0.35
20
232
18
160
1.14
0.14
3.3
2.4
56.43
65.08
ml/min/173m2
—
7
66
15
170
0.87
0.14
3.6
1.9
—
—
—
0
0
177
1755
1.09
0.08
34.2
18.2
139.45
139.79
mmol/l
1.17
172
1718
57
551
1.05
0.08
5.3
5.8
3.02
2.82
ug/l
0.05
52
493
20
186
1.08
0.07
3.2
2.0
—
—
—
0
0
17
157
1.09
0.07
2.0
1.4
—
—
—
0
0
9
87
1.04
0.07
3.8
2.2
—
—
—
0
0
9
88
1.02
0.07
1.2
1.0
—
—
—
0
0
177
1758
1.07
0.05
35.0
18.3
3.95
3.98
mmol/l
0.68
172
1716
27
261
1.04
0.02
11.5
7.2
103.85
104.08
mmol/l
0.08
27
261
21
218
0.96
0.02
9.3
5.9
—
—
—
0
0
31
316
0.98
0.00
1.7
1.5
—
—
—
0
0
166
1655
1.02
0.00
8.1
6.4
39.98
39.38
mmol/mol
0.43
160
1549
0
7
0.00
0.00
0.0
1.0
—
112.00
—
0
7
0
8
0.00
0.00
0.0
2.1
—
—
—
0
0
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
0
6
0.00
-0.00
0.0
1.0
—
118.33
—
0
6
106
1060
1.00
-0.00
3.1
2.9
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
0.24
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
7
75
0.93
-0.00
4.1
2.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_DERMATOPOLYNAS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_DERMATOPOLYNAS | 2.848 [2.14, 3.79] | < 0.001 |
| Birth year | 0.995 [0.99, 1.0] | 0.207 |
During the follow-up period (1.1.1998 — 31.12.2019), 130 out of 495 females with M13_DERMATOPOLYNAS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_DERMATOPOLYNAS | 2.483 [1.74, 3.55] | < 0.001 |
| Birth year | 0.989 [0.98, 1.0] | 0.017 |
During the follow-up period (1.1.1998 — 31.12.2019), 87 out of 295 males with M13_DERMATOPOLYNAS died.
Mortality risk
Mortality risk for people of age
years, who have M13_DERMATOPOLYNAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.296% | 0.595% |
| 5 | 1.603% | 3.498% |
| 10 | 4.077% | 7.608% |
| 15 | 7.333% | 14.038% |
| 20 | 12.719% | 22.408% |
Relationships between endpoints
↥Index endpoint: M13_DERMATOPOLYNAS – Dermatopolymyositis, unspecified
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data